Welcome to our dedicated page for Faeth Therapeutics SEC filings (Ticker: FTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Faeth Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Faeth Therapeutics's regulatory disclosures and financial reporting.
Faeth Therapeutics, Inc. reported a net loss of $186.2 million for the six months ended June 30, 2026, largely driven by a $133.0 million acquired in-process R&D charge recognized in connection with its February 2026 acquisition of Faeth Therapeutics and related programs.
Excluding that nonrecurring charge, operating costs expanded as research and development expenses rose to $27.1 million and general and administrative expenses to $28.9 million, reflecting integration of the acquired business, higher personnel costs, and stock-based compensation. Cash, cash equivalents and marketable securities totaled $186.4 million as of June 30, 2026, following a $200.0 million Series B preferred stock private placement and subsequent conversion of most preferred shares into common stock.
Post-transaction, legacy Sensei stockholders held about 4.9% of the common equity on a fully diluted basis, former Faeth holders 40.6%, and new private placement investors 54.5%. Management states that the strengthened balance sheet is expected to fund operations through key clinical milestones for lead multi-node PI3K/AKT/mTOR inhibitor PIKTOR in endometrial and HR+/HER2- breast cancer.
Faeth Therapeutics, Inc. reported financial results for the quarter ended June 30, 2026 and provided clinical and corporate updates. The company highlighted its combination with Sensei Biotherapeutics and a concurrent $200 million PIPE financing, which it says provides capital to advance its multi-node inhibitor PIKTOR across multiple cancers.
For the quarter, total operating expenses were $18,385 (in thousands), up from $5,206 (in thousands) a year earlier, driven by research and development of $9,180 (in thousands) and general and administrative expenses of $9,205 (in thousands). Net loss was $16,007 (in thousands), compared with $4,936 (in thousands), or $2.84 net loss per share versus $3.91. Cash and cash equivalents were $26,903 (in thousands) and marketable securities were $159,538 (in thousands) as of June 30, 2026.
Operationally, Faeth reported that topline results from its Phase 2 PIK-201 trial in advanced endometrial cancer are on track for year-end 2026, and that the first patient was dosed in its Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026, with initial data anticipated in 2027.
Faeth Therapeutics, Inc. has an initial beneficial ownership report from entities affiliated with Khosla Ventures, including Khosla Ventures VI, L.P. and Khosla Ventures Seed D, L.P., relating to Common Stock.
The securities are held of record by these funds, with Khosla Ventures Associates VI, LLC and Khosla Ventures Seed Associates D, LLC as general partners, and VK Services, LLC and Vinod Khosla positioned to exercise voting and investment control. Each reporting person may be deemed to have indirect beneficial ownership but expressly disclaims beneficial ownership except to the extent of its or his pecuniary interest.
Faeth Therapeutics, Inc. approved one-time supplemental performance-based stock option grants under its 2026 Equity Incentive Plan for employees who were employed as of February 19, 2026, including key executives.
The Chief Executive Officer received options for 398,018 shares, the General Counsel 84,766 shares and the Senior Vice President, Finance 30,824 shares. Each option has an exercise price equal to the closing price of the common stock on the grant date and vests in a single tranche only after a Stock Price Hurdle of $70.00 per share is achieved during a Performance Period that ends on the fourth anniversary of the grant date and at least one year has elapsed, subject to continued service. Unvested options are forfeited if the hurdle is not met or service ends, while a qualifying change in control with per-share consideration of at least $70.00 accelerates vesting.
Faeth Therapeutics, Inc. granted PAO Josiah Craver a performance-based stock option covering 30,824 shares of common stock at an exercise price of $28.37 per share. The option becomes exercisable only if the average Nasdaq closing price reaches $70.00 over 30 consecutive days and at least one year has passed, and is forfeited if the stock price hurdle is not achieved by the fourth anniversary or not met in connection with a qualifying Change in Control. Following this award, Craver holds 30,824 of these options directly.
Faeth Therapeutics, Inc. granted President and CEO Anand Kiran Parikh a performance-based stock option covering 398,018 shares of common stock at a $28.3700 exercise price, expiring in 2036. The option vests only if a sustained $70.00 stock-price hurdle and time-and-service conditions are met. In a qualifying Change in Control where per-share consideration is at least $70.00, it vests in full; if the $70.00 hurdle is not achieved by the fourth anniversary of grant, or not deemed achieved in connection with a Change in Control, the option is forfeited.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported open-market purchases of a total of 13,634 shares of common stock over three days. On June 29 and 30, 2026, and July 1, 2026, the trust bought multiple blocks of shares at weighted average prices disclosed in the filing, including 4,400 shares at $23.40 and 4,255 shares at $24.98. Following the latest transaction, the trust holds 46,688 shares of Faeth Therapeutics common stock. The footnotes state that Stephenson is the sole trustee of the revocable trust, with sole voting and investment power, while disclaiming beneficial ownership beyond his pecuniary interest.
Faeth Therapeutics, Inc.’s Chief Financial Officer Brian C. Stephenson reported multiple indirect open-market purchases of the company’s common stock. Over June 24 and June 26, 2026, a revocable trust associated with him bought a total of 15,641 shares at prices ranging from about $23.61 to $27.77 per share. Following these transactions, the trust held 33,054 shares of Faeth Therapeutics common stock. The shares are held by the Brian Stephenson Revocable Trust, where he is sole trustee with sole voting and investment power, while he disclaims beneficial ownership except to the extent of his pecuniary interest.
Faeth Therapeutics, Inc. Chief Financial Officer Brian C. Stephenson, through the Brian Stephenson Revocable Trust, reported a series of open-market purchases of the company’s common stock. Over June 22–23, 2026, the trust bought a total of 17,413 shares in eight separate transactions.
The reported weighted average purchase prices ranged from about $19.5765 to $26.31 per share across those trades. All holdings reported in this filing are indirect, held by the revocable trust for which Stephenson serves as sole trustee with sole voting and investment power, and amount to 17,413 shares after these transactions.
Faeth Therapeutics, Inc. President and CEO Anand Kiran Parikh increased his direct stake through option exercises and an open-market stock purchase. He exercised employee stock options to acquire 53,465 shares of common stock at $1.16 per share and bought an additional 2,806 shares in the open market at $19.76 per share, all on June 22, 2026. Following these transactions, he directly owns 817,699 shares of Faeth Therapeutics common stock.